Contents

20 January 2010
Vol 2, Issue 15

About The Cover

Cover image expansion

ONLINE COVER Rebound angiogenesis. Drugs that block new blood vessel formation—angiogenesis—are components of first-line therapies for a number of human cancers. However, antiangiogenic therapy can have undesirable effects on the patient, including rapid-rebound revascularization of tumors after withdrawal of the drug. In this issue, Cao and Langer propose ways to optimize antiangiogenic therapy with new drug delivery systems. [CREDIT: C. BICKEL/AAAS]